| Revision as of 14:03, 6 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 460512142 of page Sevirumab for the Chem/Drugbox validation project (updated: ''). |
Latest revision as of 20:54, 1 December 2023 edit Buidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,073 editsm Moving from Category:Experimental drugs to Category:Experimental antiviral drugs using Cat-a-lot |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
⚫ |
| verifiedrevid = 464389745 |
|
| Verifiedfields = changed |
|
|
|
<!-- Monoclonal antibody data --> |
| ⚫ |
| verifiedrevid = 447741609 |
|
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = |
|
| mab_type = |
|
| source = u |
|
| source = u |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
| Line 21: |
Line 18: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 28: |
Line 24: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| CAS_number_Ref = {{cascite|correct|CAS}} |
| ⚫ |
<!--Identifiers--> |
|
|
⚫ |
| CAS_number = 138660-96-5 |
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
| ⚫ |
| ChemSpiderID = NA |
|
|
|
| UNII = HV6MT68KKF |
| ⚫ |
| CAS_number_Ref = {{cascite|correct|??}} |
|
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ⚫ |
| CAS_number = |
|
|
⚫ |
| ChemSpiderID = none |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
|
| ChEMBL = 2108881 |
|
|
| KEGG = D05831 |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
| chemical_formula = |
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
|
|
|
|
'''Sevirumab''' ('''MSL-109''') is a ] ] for the treatment of infections with ] in patients with ].<ref>{{cite journal | vauthors = Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB | display-authors = 6 | title = A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis | journal = Antiviral Research | volume = 64 | issue = 2 | pages = 103–11 | date = November 2004 | pmid = 15498605 | doi = 10.1016/j.antiviral.2004.06.012 }}</ref><ref>{{ClinicalTrialsGov|NCT00000836|A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)}}</ref> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
{{Monoclonals for infectious disease and toxins}} |
|
|
|
|
|
] |
|
|
] |
|
|
{{antiinfective-drug-stub}} |
|
|
{{monoclonal-antibody-stub}} |